Azacitidine and lenalidomide as an alternative treatment for refractory acute myeloid leukemia: a case report

Sao Paulo Medical Journal

Juliana Todaro¹  Patrícia Weinschenker Bollmann¹  Edna Terezinha Rother¹  Auro Del Giglio¹ 

关键词: Leukemia;    myeloid;    acute;    Drug therapy;    Abnormal karyotype;    Angiogenesis inhibitors;    Azacitidine;    Leucemia mieloide aguda;    Quimioterapia;    Cariótipo anormal;    Inibidores da angiogênese;    Azacitidina;   

DOI  :  10.1590/1516-3180.2012.6790006

来源: SciELO

【 摘 要 】

CONTEXT:Refractory acute myeloid leukemia (AML) is a difficult disease to control with second or third-line chemotherapy regimens. In this report, we describe using azacitidine in combination with lenalidomide as salvage therapy.CASE REPORT:52-year-old female was diagnosed with refractory AML and high-risk cytogenetics: complex monosomal karyotype consisting of t (3, 3) in association with monosomy 7 and del 5q. Morphological remission associated with maintenance of the cytogenetic abnormality of chromosome 3 and disappearance of the abnormalities relating to chromosomes 5 and 7 was achieved after three cycles of combination therapy with azacitidine and lenalidomide.CONCLUSION:Azacitidine plus lenalidomide can be a therapeutic option for patients with refractory AML, as illustrated in this case.

【 授权许可】

CC BY   
 All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License